GE HealthCare reported third quarter revenue of $5.5 billion on October 28, up 7.2 percent, with organic revenue growth of 6.2 percent across all segments. Net income attributable to the company was $615 million, against $446 million a year earlier, and the net income margin rose to 11.1 percent from 8.7 percent. Diluted earnings per share grew 39.1 percent to $1.36, and adjusted earnings per share grew 25.1 percent to $1.34. Orders grew 4.0 percent organically, with a book to bill ratio of 1.03 times and a backlog of $23.7 billion.
President and chief executive Peter Arduini said the quarter reflected commercial execution and continued customer adoption of the company’s innovations, and that the company is raising guidance for the year on improved performance and momentum. Full year adjusted earnings per share guidance rose to $4.95 to $5.05, from $4.80 to $5.00, and organic revenue growth guidance moved to about 4.0 percent. Operating cash flow was $907 million and free cash flow $793 million, including a tariff refund of $55 million.
By segment, Advanced Imaging Solutions revenue rose 6.1 percent to $3.873 billion, Pharmaceutical Diagnostics rose 13.0 percent to $846 million, and Patient Care Solutions rose 8.5 percent to $793 million, with segment earnings in Patient Care Solutions up 148.8 percent. The company also disclosed that Jeannette Bankes, who leads Patient Care Solutions, will leave for a chief executive role elsewhere, with Neal Sandy taking the role on November 16, 2026.
The quarter’s deal is radiopharmaceuticals. In October the company announced plans to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash, a transaction expected to close in the first half of 2027, giving GE HealthCare what it called a final mile footprint for PET radiopharmaceutical supply in the United States.